90 related articles for article (PubMed ID: 18775979)
1. Differential allelic expression in leukoblast from patients with acute myeloid leukemia suggests genetic regulation of CDA, DCK, NT5C2, NT5C3, and TP53.
Jordheim LP; Nguyen-Dumont T; Thomas X; Dumontet C; Tavtigian SV
Drug Metab Dispos; 2008 Dec; 36(12):2419-23. PubMed ID: 18775979
[TBL] [Abstract][Full Text] [Related]
2. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
3. Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.
Falk IJ; Fyrberg A; Paul E; Nahi H; Hermanson M; Rosenquist R; Höglund M; Palmqvist L; Stockelberg D; Wei Y; Gréen H; Lotfi K
Am J Hematol; 2013 Dec; 88(12):1001-6. PubMed ID: 23873772
[TBL] [Abstract][Full Text] [Related]
4. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
5. NT5C3 polymorphisms and outcome of first induction chemotherapy in acute myeloid leukemia.
Cheong HS; Koh Y; Ahn KS; Lee C; Shin HD; Yoon SS
Pharmacogenet Genomics; 2014 Sep; 24(9):436-41. PubMed ID: 25000516
[TBL] [Abstract][Full Text] [Related]
6. Pathway-based pharmacogenomics of gemcitabine pharmacokinetics in patients with solid tumors.
Mitra AK; Kirstein MN; Khatri A; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK
Pharmacogenomics; 2012 Jul; 13(9):1009-21. PubMed ID: 22838949
[TBL] [Abstract][Full Text] [Related]
7. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
8. Genetic factors influencing cytarabine therapy.
Lamba JK
Pharmacogenomics; 2009 Oct; 10(10):1657-74. PubMed ID: 19842938
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
Xie XT; Jiang SY; Li BS; Yang LL
Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
[TBL] [Abstract][Full Text] [Related]
10. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.
Giovannetti E; Del Tacca M; Mey V; Funel N; Nannizzi S; Ricci S; Orlandini C; Boggi U; Campani D; Del Chiaro M; Iannopollo M; Bevilacqua G; Mosca F; Danesi R
Cancer Res; 2006 Apr; 66(7):3928-35. PubMed ID: 16585222
[TBL] [Abstract][Full Text] [Related]
11. Association of polymorphisms of cytosine arabinoside-metabolizing enzyme gene with therapeutic efficacy for acute myeloid leukemia.
Xu PP; Chen BA; Feng JF; Cheng L; Xia GH; Li YF; Qian J; Ding JH; Lu ZH; Wang XM; Xu K; Schultz M
Chin Med J (Engl); 2012 Jun; 125(12):2137-43. PubMed ID: 22884143
[TBL] [Abstract][Full Text] [Related]
12. Potential mechanisms of resistance to cytarabine in AML patients.
Galmarini CM; Thomas X; Calvo F; Rousselot P; El Jafaari A; Cros E; Dumontet C
Leuk Res; 2002 Jul; 26(7):621-9. PubMed ID: 12008078
[TBL] [Abstract][Full Text] [Related]
13. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
[TBL] [Abstract][Full Text] [Related]
14. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK; Crews KR; Pounds S; Cao X; Feldberg T; Ghodke Y; Gandhi V; Plunkett W; Dolan ME; Hartford C; Raimondi S; Campana D; Downing J; Rubnitz JE; Ribeiro RC; Lamba JK
J Pharmacol Exp Ther; 2011 Oct; 339(1):9-23. PubMed ID: 21712425
[TBL] [Abstract][Full Text] [Related]
15. Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.
Toffalorio F; Giovannetti E; De Pas T; Radice D; Pelosi G; Manzotti M; Minocci D; Spaggiari L; Spitaleri G; Noberasco C; Catania C; Boselli S; Danesi R; de Braud F
Pharmacogenomics J; 2010 Jun; 10(3):180-90. PubMed ID: 19901957
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic activity of gemcitabine and correlation with expression profile of drug-related genes in human lymphoid cells.
Giovannetti E; Mey V; Loni L; Nannizzi S; Barsanti G; Savarino G; Ricciardi S; Del Tacca M; Danesi R
Pharmacol Res; 2007 Apr; 55(4):343-9. PubMed ID: 17296311
[TBL] [Abstract][Full Text] [Related]
17. SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival.
Mahlknecht U; Dransfeld CL; Bulut N; Kramer M; Thiede C; Ehninger G; Schaich M
Leukemia; 2009 Oct; 23(10):1929-32. PubMed ID: 19458626
[No Abstract] [Full Text] [Related]
18. Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine.
Galmarini CM; Thomas X; Graham K; El Jafaari A; Cros E; Jordheim L; Mackey JR; Dumontet C
Br J Haematol; 2003 Jul; 122(1):53-60. PubMed ID: 12823345
[TBL] [Abstract][Full Text] [Related]
19. Expression Levels of Human Equilibrative Nucleoside Transporter 1 and Deoxycytidine Kinase Enzyme as Prognostic Factors in Patients with Acute Myeloid Leukemia Treated with Cytarabine.
Candelaria M; Corrales-Alfaro C; Gutiérrez-Hernández O; Díaz-Chavez J; Labardini-Méndez J; Vidal-Millán S; Herrera LA
Chemotherapy; 2016; 61(6):313-8. PubMed ID: 27119162
[TBL] [Abstract][Full Text] [Related]
20. 5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.
Díaz-Santa J; Rodríguez-Romanos R; Coll R; Osca G; Pratcorona M; González-Bártulos M; Garrido A; Angona A; Talarn C; Tormo M; Arnan M; Vives S; Salamero O; Tuset E; Lloveras N; Díez I; Zamora L; Bargay J; Sampol A; Cruz D; Vila J; Sitges M; Garcia A; Vall-Llovera F; Esteve J; Sierra J; Gallardo D;
Eur J Haematol; 2022 Dec; 109(6):755-764. PubMed ID: 36063368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]